

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 13-11-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 04-8-2007 TO BE PUBLISHED ON 14-11-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

913/2007	<u>30-07-2007</u> Santoni S.p.A, Italy (Priority 25-7-06 USA)	“Knitting machine with latch needles and without sinkers”
914/2007	OTV SA, France (Priority 01-8-06 France)	“Method for treating water by ballasted flocculation-sedimentation, including continuous measurement of the ballast, and system corresponding thereto”
915/2007	N.V. Ovganon Netherlands (Priority 08-8-06 Europe)	“An orally active thrombin inhibitor”
916/2007	Honda Motor Co. Ltd. Japan (Priority 14-9-06 Japan)	“ Water cooled internal combustion engine having radiator”
917/2007	Sanofi-Aventis France (Priority 31-7-06 France)	“N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof”
918/2007	Novartis AG, Switzerland (Priority 02-8-06 USA)	“Organic compounds”
919/2007	<u>31-7-2007</u> Cytokinetics, Incorporated USA (Priority 01-8-06 USA)	“ Certain chemical entities, compositions, and methods”
920/2007	Cytokinetics, Incorporated USA (Priority 02-8-06 USA)	“ Certain chemical entities, compositions, and methods”
921/2007	Sanofi-Aventis France (Priority 02-8-06 Germany)	“Iminoimidazopyridine derivatives having antithrombotic activity”
922/2007	Cytokinetics, Incorporated USA (Priority 02-8-06 USA)	“Certain chemical entities, compositions, and methods”
923/2007	AstraZeneca AB, Sweden (Priority 03-8-06 USA)	“Antibodies directed to α V β 6 and uses thereof”

924/2007	Sasol Technology (Proprietary) Limited, South Africa (Priority 01-8-06 South Africa)	“Method for the production of synthesis gas and of operating a fixed bed dry bottom gasifier”
	<u>02-8-2007</u>	
925/2007	Nestec S.A., Switzerland	“Dispenser for preparing a nutritional composition”
	<u>03-8-2007</u>	
926/2007	Bayer CropScience AG, Germany (Priority 05-8-06 Germany)	“Novem microemulsion concentrates”
927/2007	Bayer CropScience AG, Germany (Priority 05-8-06 Germany)	“Novem microemulsion concentrates”
928/2007	Bayer CropScience AG, Germany (Priority 15-8-06 Japan)	“Insecticidal isoxazolines”
929/2007	AstraZeneca AB, Sweden (Priority 03-8-06 USA)	“Targeted binding agents directed to pdgfr-alpha and uses thereof”
930/2007	MERZ Pharma GMBH and Co. KGaA Germany (Priority 04-8-06 US)	“Pyrazolopyrimidines, a process for their preparation and the use as medicine”
931/2007	MERZ Pharma GMBH and Co. KGaA Germany (Priority 04-8-06 US)	“Pyrazolopyrimidines, a process for their preparation and their use as medicine”
932/2007	MERZ Pharma GMBH and Co. KGaA Germany (Priority 04-8-06 US)	“Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine”
933/2007	Takeda Pharmaceutical Company Limited, Japan (Priority 04-8-06 Japan)	“ Fused heterocyclic derivative and use thereof”
	<u>04-8-2007</u>	
934/2007	Wyeth, USA (Priority 04-8-06 USA)	“6-carboxy-normorphinan derivatives, synthesis and uses thereof”
935/2007	Wyeth, USA (Priority 04-8-06 USA)	“Formulations for parenteral delivery of compounds and uses thereof”
936/2007	BASF Aktiengesellschaft Germany	“Substituted azolin-2-yl-amino compounds”

(Priority 07-8-06 US)

937/2007	Sanofi-Aventis France (Priority 25-5-04 France) Divisional	“A salt of a tetrahydroisoquinolylsulphonamide-derived compound”
938/2007	Enanta Pharmaceuticals, Inc, USA (Priority 04-8-06 US)	“Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors”
939/2007	Enanta Pharmaceuticals, Inc, USA (Priority 04-8-06 US)	“Tetrazolyl macrocyclic hepatitis C serine protease inhibitors”

CORRIGENDUM

In the Gazette of Pakistan Part-V under the heading “**Sealing fees due**” the sealing fees due after expiry of opposition period i.e. 4 months which may be read as follows:

Application No.	Serial No	Gazette Published	Sealing Due
84/98	139246	16-5-2007	16-9-2007
125/98	139247	16-5-2007	16-9-2007
587/98	139248	16-5-2007	16-9-2007
664/98	139249	16-5-2007	16-9-2007
503/2001	139250	16-5-2007	16-9-2007
852/2001	139251	16-5-2007	16-9-2007
396/2002	139252	16-5-2007	16-9-2007
264/2005	139253	16-5-2007	16-9-2007
520/96	139254	16-5-2007	16-9-2007
334/99	139255	16-5-2007	16-9-2007
465/97	139256	16-5-2007	16-9-2007
794/97	139257	16-5-2007	16-9-2007
820/2002	139258	16-5-2007	16-9-2007
396/97	139259	23-6-2007	23-10-2007
839/92	139260	23-6-2007	23-10-2007
88/99	139261	23-6-2007	23-10-2007

497/99	139262	27-7-2007	27-11-2007
867/99	139263	27-7-2007	27-11-2007
849/2001	139264	27-7-2007	27-11-2007
297/2005	139265	27-7-2007	27-11-2007
1092/98	139266	27-7-2007	27-11-2007
71/2007	139267	27-7-2007	27-11-2007
928/04	139268	1-8-2007	1-12-2007
28/2005	139269	1-8-2007	1-12-2007
320/98	139270	1-8-2007	1-12-2007
440/2000	139271	1-8-2007	1-12-2007
609/2003	139272	1-8-2007	1-12-2007
19/2005	139273	1-8-2007	1-12-2008
892/98	139274	5-9-2007	5-1-2008
420/2007	139275	5-9-2007	5-1-2008
515/99	139276	5-9-2007	5-1-2008
467/2000	139277	5-9-2007	5-1-2008
49/2003	139278	5-9-2007	5-1-2008
156/2003	139279	3-10-2007	3-2-2008
473/2003	139280	3-10-2007	3-2-2008
687/2002	139281	3-10-2007	3-2-2008
663/2003	139282	3-10-2007	3-2-2008
1243/2005	139283	3-10-2007	3-2-2008
937/2005	139284	3-10-2007	3-2-2008

Will appear in the Gazette ----- 2007.